- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
ENLV
NASDAQ
Week ended 24 Jul 2026
Weekly Investor Report
Enlivex Therapeutics Ltd · Healthcare · Biotechnology
Latest close
4.20 USD
-10.3%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -66.4% below the Trend Line and sits at 0.4% of its 52-week range. The latest completed week returned -10.3%, after a -50.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 51/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: volume confirmation is below normal; earnings are due in 36d.
Setup score
12
out of 100
Latest Close
4.20 USD
24 Jul 2026
1W Return
-10.3%
latest completed week
4W Return
-50.9%
short-term follow-through
12W Return
-65.7%
quarterly tape
Trend Breadth
13.5%
7 of 52 weeks active
Volume Ratio
0.3x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-10.3%
Latest completed week; four-week move -50.9%.
Indicator stack
7/25
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 37.99%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
51/100 conviction; expected move 26.4%.
News sentiment
55/100
56 relevant articles in the latest sentiment read.
Event risk
36d
Next report is scheduled for 04 Sep 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -66.4% below the Trend Line and sits at 0.4% of its 52-week range. The latest completed week returned -10.3%, after a -50.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0112-week average 0.05
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.01Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -50.9% over four weeks, -65.7% over 12 weeks, and -75.0% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year7
Trend breadth13.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.37Latest activity-pressure read.
Pressure change-7.5%Four-week change in activity pressure.
Leadership-73.28Latest relative-leadership reading.
RS change-43.1%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 70%
Model confidence 57%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength62/100Blend of value, momentum, and quality. Underlying universe rank 39; rank 1 is best.
Value55/100Relative valuation strength. Underlying universe rank 46; rank 1 is best.
Quality54/100Profitability and accounting quality. Underlying universe rank 47; rank 1 is best.
Momentum56/100Medium-term price momentum. Underlying universe rank 45; rank 1 is best.
Growth56/100Revenue and earnings growth. Underlying universe rank 45; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -15.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- -0.6% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -14.7% Net share repurchases relative to market value.
- Shareholder yield
- -14.7% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
ENLV shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.22, expected move of 26.4%, and Sharemaestro trend signal inactive.
Conviction51/100
Expected move26.4%
Put/call volume0.22
Insider activity-
No recent insider transactions are stored for this company.
News sentiment55/100
Weighted news tone is neutral across 56 relevant articles.
14 positive · 36 neutral · 6 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings36dNext report is scheduled for 04 Sep 2026; event risk rises as the date approaches.
Options expected move26.4%Nearest-chain priced movement where available.
52-week drawdown-86.7%Distance below the 52-week high.
13-week volatility9.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher6 of 2620 weeks finished lower.
Best week+14.9%Week of 6 Feb.
Worst week-31.8%Week of 17 Jul.
Latest week-10.3%Week of 24 Jul.
Shape of recent returns
Strong gains3
Modest gains3
Flat weeks0
Modest losses3
Sharp losses17
Recent vol9.3%13-week weekly-return volatility.
Base vol12.7%52-week weekly-return volatility.
Up/down split19/32Count of positive and negative weeks in the 52-week window.
Average skew10.1% / -8.9%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average1.3%
Trend breadth51.0%
Trend51.0%active weekly trend signals
MD75.0%positive activity pressure
RS48.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average0.5%
Trend breadth67.0%
Trend67.0%active weekly trend signals
MD72.0%positive activity pressure
RS65.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape14/100
Trend, activity pressure, participation, and risk combine to a 14/100 tape read.
Indicator analysis9/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.01; No reversal markers Next-Week ExpectancyNegative 37.99%Next-week expectancy is negative with a 37.99% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors56/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 89; Small Cap Core rank 51 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options35/100ENLV shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.22, expected move of 26.4%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 26.4% Sentiment55/100Weighted news tone is neutral across 56 relevant articles.
ENLV|Enlivex Therapeutics Ltd|Price:4.250|Chg%:+0.050 Insiders50/100No recent insider transaction evidence is stored.
Earnings36dNext report is scheduled for 04 Sep 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 4.20 USD | -10.3% | 12.51 USD | 21.43 USD | -1.37 | -73.28 | 460.8K | Off |
| 17 Jul 2026 | 4.68 USD | -31.8% | 12.74 USD | 21.64 USD | -1.32 | -71.27 | 611.2K | Off |
| 10 Jul 2026 | 6.86 USD | -13.3% | 13.00 USD | 21.85 USD | -1.34 | -60.46 | 2.5M | Off |
| 3 Jul 2026 | 7.91 USD | -7.4% | 13.24 USD | 22.03 USD | -1.34 | -54.48 | 1.9M | Off |
| 26 Jun 2026 | 8.55 USD | -8.3% | 13.58 USD | 22.21 USD | -1.27 | -51.20 | 2.4M | Off |
| 19 Jun 2026 | 9.33 USD | -7.2% | 13.78 USD | 22.40 USD | -1.10 | -49.98 | 1.2M | Off |
| 12 Jun 2026 | 10.05 USD | -5.6% | 13.92 USD | 22.61 USD | -1.06 | -45.42 | 1.1M | Off |
| 5 Jun 2026 | 10.65 USD | -12.4% | 14.08 USD | 22.82 USD | -1.04 | -41.35 | 2.7M | Off |
| 29 May 2026 | 12.15 USD | 12.9% | 14.22 USD | 23.01 USD | -1.05 | -36.67 | 3.8M | Off |
| 22 May 2026 | 10.76 USD | -0.4% | 14.34 USD | 23.18 USD | -1.17 | -42.75 | 596.4K | Off |
| 15 May 2026 | 10.81 USD | -6.4% | 14.51 USD | 23.36 USD | -1.05 | -42.39 | 1.1M | Off |
| 8 May 2026 | 11.55 USD | -5.6% | 14.68 USD | 23.56 USD | -0.90 | -39.24 | 1.3M | Off |
| 1 May 2026 | 12.24 USD | -8.2% | 14.87 USD | 23.75 USD | -0.54 | -32.80 | 1.5M | Off |
| 24 Apr 2026 | 13.33 USD | 3.4% | 15.00 USD | 23.94 USD | -0.18 | -26.43 | 2.0M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.